Oxandrolone tablets are again available inside the U.S. by BTG, bearing the new brand name Oxandrin. BTG purchased rights to the drug from Searle and it is now manufactured for the new purpose of treating HIV/AIDS related wasting syndrome. Anavar is a mild anabolic with low androgenic activity. Its reduced androgenic activity is due to the fact that it is a derivative of dihydrotestosterone (DHT). Although one might think that this would make it a more androgenic steroid, it in fact creates a steroid that is less androgenic because it is already “5-alpha reduced”. In other words, it lacks the capacity to interact with the 5-alpha reductase enzyme and convert to a more potent “dihydro° form. It is a simple matter of where a steroid is capable of being potentiated in the body, and with oxandrolone we do not have the same potential as testosterone, which is several times more active in androgen responsive tissues compared to muscle tissue due to its conversion to DHT. It essence oxandrolone has a balanced level of potency in both muscle and androgenic target tissues such as the scalp, skin and prostate. This is a similar situation as is noted with Primobolan and Winstrol, which are also derived from dihydrotestosterone yet not known to be very androgenic substances.